We found that 39 of 41 (95.1%) YAP-positive samples also were positive for NEDD4, whereas only 20 of 36 (55.6%) TAZ-positive samples were positive for NEDD4 (P < .0001) (Figures 12E–G), suggesting that NEDD4 may be a direct target of YAP in HCC. The gene discussed is NEDD4; the disease is hepatocellular carcinoma.